%0 Journal Article
%T Psychedelic Drug Therapy for Mental Disorders?
%A John R. Rossiter
%J Open Journal of Medical Psychology
%P 150-171
%@ 2165-9389
%D 2023
%I Scientific Research Publishing
%R 10.4236/ojmp.2023.123010
%X <strong>Objective:</strong> Psychedelic drug therapy is banned in all countries of the world except Australia, where the government regulatory watchdog, the Therapeutic Goods Administration, is planning to allow approved psychiatrists, as of July 1, 2023, to prescribe psilocybin to treat depression and MDMA to treat post-traumatic stress disorder, a move precipitated by the U.S. Food and Drug Administration¡¯s designation of these two drugs as ¡°breakthrough therapy¡±. The objective of the present article is to demonstrate that the evidence on which the FDA and then the TGA relied is irretrievably flawed and should be dismissed. <strong>Method:</strong> Expert review of psychedelic therapy clinical trials and specifically of the methodology and measures used. <strong>Results:</strong> The present review demonstrates that the studies the U.S. FDA and the Australian TGA relied on to approve these two psychedelic drugs for therapy are irretrievably flawed. All future trials will follow the same procedure and are therefore bound to be flawed as well. <strong>Conclusions:</strong> Psychedelic drug studies have so far provided no trustworthy evidence of their effectiveness for treating mental disorders and are not likely to produce this evidence in the future. Psychedelic drug therapy is in any event impractical because of its specialized training requirements and very high treatment costs. It is also dangerous because false publicity about its effectiveness will almost certainly lead to unsupervised self-dosing with drugs that not only are illegal but have an unacceptably high addiction rate.
%K Psychedelic Drugs
%K Psychotherapy
%K Mental Disorders
%K Clinical Trials
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=126589